1 in 10 American Adults Have Used a GLP-1 Medication in the Past Year

GLP-1 medications have gone from a niche diabetes treatment to one of the most talked about topics in healthcare. New research from the Centers for Disease Control and Prevention puts a number on how common they’ve become: about one in 10 U.S. adults reported taking one of these drugs during the past year.

The findings, published in the CDC’s Morbidity and Mortality Weekly Report, come from survey data the CDC collected through its Rapid Surveys System from July to August 2025.

Many users aren’t taking them as prescribed

Usage is only part of the story. The researchers found that about two in five GLP-1 users said they had changed the way they take the medication from how it was prescribed. Cost and availability were among the reasons people gave for not following the prescription.

In other words, many people who start these drugs are adjusting their doses or how often they take them, and often because of the price or because they can’t get the medication.

Compounded versions are common

The study also found that about one in five GLP-1 users reported taking a compounded version of the drug. These products have not been reviewed by the U.S. Food and Drug Administration for safety, effectiveness, or quality before they are sold. Some people turn to them as a lower cost or easier to find alternative, but they don’t have the same oversight as the brand name medications.

What the researchers say

The authors note that these changes in how people use GLP-1 medications reflect, in part, the cost and access challenges people face. They suggest that future research look at how real world use, including dose and frequency adjustments, affects the safety and effectiveness of these drugs.

What this means for you

With this many people using GLP-1 medications, coverage and cost questions aren’t going away. Whether you’re an individual weighing your plan options or an employer deciding how to handle these drugs in your benefits, it’s worth knowing what your plan covers and what it doesn’t. If you have questions about GLP-1 coverage on your health plan, reach out to us. We’re happy to help you sort through your options.

Two notes: the article says the survey ran July to August 2025, so I kept that date even though the medicalxpress headline is from November 2026. The closing section is general wording I added, not from the article, so edit or cut it as you like.